Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors

• Published in: Acta dermato-venereologica Vol. 97; no. 6; pp. 731 - 734
• Main Authors: Darrigade, Anne-Sophie, Milpied, Brigitte, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Laharie, David, Zerbib, Frank, Beylot-Barry, Marie, Jouary, Thomas, Taïeb, Alain, Ezzedine, Khaled, Seneschal, Julien
• Format: Journal Article
• Language: English
• Published: Sweden Medical Journals Sweden 09.06.2017
• Subjects: Adolescent; Adult; Aged; Anti-Inflammatory Agents - adverse effects; arthritis; Arthritis - diagnosis; Arthritis - drug therapy; Arthritis - immunology; Dermatitis - diagnosis; Dermatitis - drug therapy; Dermatitis - immunology; Drug Eruptions - etiology; Drug Eruptions - pathology; Female; Humans; Inflammatory Bowel Diseases - diagnosis; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - immunology; inflammatoryboweldisease; inhibitors; Male; Middle Aged; Observer Variation; psoriasiformeruption; psoriasis; Psoriasis - chemically induced; Psoriasis - pathology; Reproducibility of Results; Retrospective Studies; Risk Factors; Scalp Dermatoses - chemically induced; Scalp Dermatoses - pathology; Severity of Illness Index; Sex Factors; Skin - drug effects; Skin - pathology; Time Factors; TNF-α; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - immunology; tumournecrosisfactor; Young Adult
• ISSN: 0001-5555; 1651-2057
• DOI: 10.2340/00015555-2636

Psoriasiform eruptions are a classical adverse skin reaction of tumour necrosis factor (TNF)-α inhibitors. The aim of this study was to identify the association between the severity or pattern of psoriasiform reactions and the underlying disease. A retrospective study was conducted between January 2012 and May 2015. Adult patients who developed psoriasiform eruptions whilst being treated with TNFα inhibitors were included. For each patient, 3 independent blinded dermatologists graded twice the severity of the lesions according to 6 clinical psoriasiform eruption types. Inter- and intra-individual kappa tests were performed to evaluate the robustness of the scoring system. The association between severity score levels or the pattern of reactions and the underlying disease was assessed. The severity scoring system showed good inter- and intra-observer reproducibility. Women patients treated with TNFα inhibitors for inflammatory bowel diseases showed a higher risk of developing severe reactions with scalp and skin-fold involvement.